Navigation Links
Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
Date:10/8/2009

QUEBEC CITY, Oct. 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center ("ECBC") Research & Technology Directorate. Medicago will work with ECBC to investigate the affordable production of industrial enzymes in the field of biofuels. This new project builds on Medicago's proprietary plant-based manufacturing platform and its potential for applications beyond the biological drug market.

"While we remain focused on advancing our core influenza programs, biotechnology markets are quickly evolving and offer new opportunities to increase shareholder value," said Louis P. Vezina, Chief Scientific Officer of Medicago. "The world enzyme market is currently estimated to be worth US$4 billion and is projected to increase 5.7% per year. Moreover, the high cost of enzymes is a major hurdle in the production of biofuels using biomass. We believe our manufacturing platform could be suitable for the production of affordable enzymes as plants are uniquely capable of efficient protein expression at high yields and low costs. We look forward to playing a role in the U.S. Army's efforts to accelerate the economical production of biofuels."

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release.

SOURCE Medicago Inc.


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago begins human clinical testing with its avian flu pandemic vaccine
2. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago succesfully expresses VLP antigen for A H1N1 strain
5. Medicago initiates work on Swine Flu strain
6. NeoStem, Inc. Awarded NIH Research and Research Infrastructure Grand Opportunities Grant
7. Morphotek(R), Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins
8. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
9. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
10. Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness
11. Hanson Technologies, Inc. Awarded Patent for its Advanced Food Pathogen Detection System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 Scientists propose in Nature ... in Gaucher and maybe other lysosomal storage diseases as ... than current therapies. An international research team ... which also included investigators from the University of Lübeck ... Feb. 22. The study was conducted in mouse models ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , ... from around the world, is pleased to announce the 2nd annual Precision Medicine ... This premier, online-only conference focused on the development and advancements in precision medicine. ...
(Date:2/22/2017)... MOINES, Iowa , Feb. 22, 2017 Origin (Origin ... agricultural biotechnology trait and seed provider, and Arcadia ... -based company that develops and commercializes agricultural productivity traits and nutritional ... a key corn biotechnology product developed in China ... of global regulatory trials. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech ... as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins ... Pennside after more than a decade with leading market research firm, GfK. He ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):